Table 3. Genotypic Resistance at Baseline in ACTG 368.
| Drug / Class | Resistance Pattern | ABC+IDV+EFV (n=97) |
IDV+EFV (n=89) |
Total (n=186) |
|---|---|---|---|---|
| nRTI | NAMsa alone | 5 (5%) | 4 (4%) | 9 (5%) |
| NAMs+184Vb | 63 (65%) | 54 (61%) | 117 (63%) | |
| NAMs+69D or 74V | 2 (2%) | 2 (2%) | 4 (2%) | |
| NAMs+184V+69D or 74V | 5 (5%) | 3 (3%) | 8 (4%) | |
| M184V alone | 19 (20%) | 16 (18%) | 35 (19%) | |
| M184V + T69D or L74V | 0 (0%) | 1 (1%) | 1 (0.5%) | |
| Q151Mc complex | 0 (0%) | 2 (2%) | 2 (1%) | |
| No nRTI resistance | 3 (3%) | 7 (8%) | 10 (5%) | |
| NNRTI | K103N alone | 5 (5%) | 2 (2%) | 7 (4%) |
| Y188L | 2 (2%) | 0 (0%) | 2 (1%) | |
| G190A/S | 3 (3%) | 0 (0%) | 3 (2%) | |
| P236L | 0 (0%) | 1 (1%) | 1 (0.5%) | |
| No NNRTI resistance | 87 (%) | 86 (%) | 174 (94%) | |
| IDV | Primary Mutationsd | 0 (0%) | 0 (0%) | 0 (0%) |
| Secondary Mutationse | ||||
| 0 | 50 (52%) | 47 (53%) | 97 (52%) | |
| 1 | 32 (33%) | 36 (40%) | 68 (37%) | |
| 2 | 13 (13%) | 6 (7%) | 19 (10%) | |
| 3 | 2 (2%) | 0 (0%) | 2 (1%) |
a
NAMs include any one of the following reverse transcriptase mutations: M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, K219E/Q.
b
1 sample, from subject in the ABC arm had Q151M in addition to NAMs + M184V.
c
Q151M complex is defined as the presence of one or more of the following reverse transcriptase mutations: A62V, V75I, F77L, F116Y, Q151M.
d
Primary or major IDV resistance mutations are defined as one or more of the following protease mutations: M46I/L, V82A/F/T, I84V.
e
Secondary or minor IDV resistance mutations are defined as one or more of the following protease mutations: L10I/R/V, K20M/R, L24I, V32I, M36I, I54V, A71V/T, G73S/A, V77I, L90M.